Clinical trials: HDV
HDV Infection, HBV Infection
Hepatitis D Virus Infection Among Hepatitis B Virus Surface Antigen Positive Individuals
Globally, about 248 million people are chronic HBV surface antigen carriers, and about 5% of them also had hepatitis delta virus (HDV) infection as well. The prevalence of HBsAg in Egypt is intermediate (2-7%) .
- Trial name
- NCT04038372
- Volunteers
- 186 people
- Sponsor
- Assiut University
Chronic Hepatitis B Infection, Chronic Hepatitis D Infection
The Safety and Efficacy of Sequential Treatment of Ropeginterferon Alfa-2b (P1101) and Anti-PD1 in Interferon-Naive Adults With Chronic Hepatitis B or D Infection
Primary objective: To evaluate the safety and tolerability of sequential administration of P1101 and anti-PD1 in patient with chronic hepatitis B or D infection Secondary objectives: 1.
- Trial name
- NCT04638439
- Testing
- P1101 + Nivolumab + Entecavir
- Where
- 5 sites in Taiwan
- Volunteers
- 20 people
- Sponsor
- PharmaEssentia
Hepatitis D
Immunological and Virological Characterization of Patients With Chronic HBV-HDV Infection: Outcomes and Response to Bulevirtide Treatment
Pharmacological, single-center, non-profit observational study. The present study is part of a cooperation project between the SC Gastroenterology and Hepatology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (Milan…
- Trial name
- MPR_BD (NCT06504485)
- Testing
- Bulevirtide
- Where
- Italy
- Volunteers
- 192 people
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Diabetes Mellitus, Type 1
Comparison of Hepatic Directed Vesicle (HDV)-Insulin Lispro Versus Insulin Lispro to Further Improve Glycemic Control
Multi-Center, double blind, active comparator controlled multiple dose safety, tolerability and efficacy study
- Trial name
- NCT03096392
- Testing
- HDV insulin lispro 100 UNT/ML, Insulin Lispro 100 UNT/ML
- Where
- 5 sites in United States
- Volunteers
- 46 people
- Sponsor
- Diasome Pharmaceuticals
Hepatitis D Virus Infection
HDV Screening Study
This is a territory-wide cross-sectional study of all individuals living with HIV/HBV coinfection and HBV-related HCC.
- Trial name
- NCT06889805
- Where
- Hong Kong
- Volunteers
- 300 people
- Sponsor
- Grace Lai Hung Wong
Chronic Viral Hepatitis B With Delta-agent
Myrcludex B in Combination With Peginterferon Alfa-2a Versus Peginterferon Alfa-2a Alone in Patients With Chronic Viral Hepatitis B With Delta-agent
Randomised, Comparative, Parallel-Arm Study to Assess Efficacy and Safety of Myrcludex B in Combination with Peginterferon Alfa-2a Versus Peginterferon Alfa-2a Alone in Patients with Chronic Viral Hepatitis B with Delta-agent
- Trial name
- NCT02888106
- Testing
- Myrcludex B, PEG IFN alfa-2a, Tenofovir
- Where
- 7 sites in Russia
- Volunteers
- 90 people
- Sponsor
- Hepatera Ltd.
Compensated Liver Disease (Disorder), Hepatitis D, Chronic
Finite Treatment of Hepatitis Delta With Bulevirtide: Identification of Biomarkers Associated With Sustained Control of HDV Infection
Finding biomarkers for stopping bulevirtide treatment of patients with hepatitis delta
- Trial name
- BUL-STOP (NCT06603311)
- Testing
- Stop Treatment with Bulevertide in patients with compensated liver disease and chronic HDV infection
- Where
- 5 sites in Germany, Italy
- Volunteers
- 20 people
- Sponsor
- Hannover Medical School
Chronic Hepatitis D Infection
Lonafarnib With and Without Ritonavir in HDV (LOWR-1)
To Evaluate the Safety and Efficacy of Lonafarnib with and without Ritonavir Boosting in Adults With Genotype 1 Chronic Hepatitis D Virus (HDV) Infection (LOWR-1).
- Trial name
- LOWR-1 (NCT02430181)
- Testing
- lonafarnib, peginterferon alfa-2a, ritonavir
- Where
- Turkey (Türkiye)
- Volunteers
- 21 people
- Sponsor
- EIT Pharma, Inc.
Hepatitis D
Treatment of Chronic Delta Hepatitis With Lonafarnib and Ritonavir
Background: Chronic hepatitis D is a liver disease caused by the hepatitis D virus (HDV). It can be severe and progressive. Most people with hepatitis D will develop scarring and damage to the liver.
- Trial name
- NCT02511431
- Testing
- Lonafarnib, Ritonavir
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Chronic Hepatitis D
Ezetimibe for Patients With Chronic Hepatitis D
Ezetimibe possesses pharmacophore features to inhibit NTCP, the receptor required for HBV and HDV hepatocyte entry that include two hydrophobes and one hydrogen bond acceptor.
- Trial name
- NCT03099278
- Testing
- Ezetimibe
- Where
- Pakistan
- Volunteers
- 20 people
- Sponsor
- Ziauddin Hospital
Chronic Hepatitis D Infection
A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)
This is a Phase 3, global, randomized, open-label, multicenter, trial evaluating brelovitug (BJT-778) vs bulevirtide for the treatment of chronic hepatitis delta infection (CHD).
- Trial name
- NCT07200908
- Testing
- Brelovitug 300 mg, Bulevirtide 2 mg and Brelovitug - 300 mg
- Where
- 57 sites in Austria, Czechia and 10 more
- Volunteers
- 172 people
- Sponsor
- Mirum Pharmaceuticals, Inc.
Hepatitis D, Transmission
Mother-to-child Hepatitis D Transmission
HBV can be transmitted from mother-to-child, with a risk increasing according to maternal HBV DNA during pregnancy. HDV is a defective virus using HBs Ag for its own replication.
- Trial name
- NCT02044055
- Where
- France
- Volunteers
- 54 people
- Sponsor
- Hopital Lariboisière
HDV
Thailand HDV Cohort
There is very limited data of HDV in Thailand. As both HDV and HIV can accelerate the HBV course and increased the risk of death, particularly, among those with low CD4 cells/count, therefore, HDV burden in this special…
- Trial name
- NCT05350865
- Where
- 4 sites in Thailand
- Volunteers
- 3,296 people
- Sponsor
- The HIV Netherlands Australia Thailand Research Collaboration
Hepatitis B, Hepatitis D
Prevalence and Clinical Characterization of Hepatitis D Virus (HDV) Infection Among Sudanese Patients With Hepatitis B Virus
Background: Sudan has a high prevalence of hepatitis B surface antigen (HBsAg), exceeding 8%. The prevalence of hepatitis B varies across different regions of Sudan, ranging from 6.8% in central Sudan to as high as 26% in…
- Conditions
- Hepatitis B, Hepatitis D, Viral Hepatitis
- Trial name
- NCT06360484
- Testing
- investigations for Hepatitis D virus
- Where
- Sudan
- Volunteers
- 90 people
- Sponsor
- National Center for Gastroentestinal and Liver Disease
Hepatitis D
A Study to Compare P1101 Plus TAF With or Without UDCA in Patients With HBV and HDV Co-Infection
This is an open-label, randomized, multi-center study in patients with chronic HBV and HDV co-infection.
- Trial name
- NCT05467553
- Testing
- Ursodeoxycholic acid, Ropeginterferon alfa-2b, Tenofovir Alafenamide
- Where
- 2 sites in Taiwan
- Volunteers
- 30 people
- Sponsor
- National Taiwan University Hospital
HDV, HDV Infection
ePro Diary - HDV ( MACROLIVER )
This study is part of the MACROLIVER Project, which aims to develop a digital tool for patients and their caregivers to manage liver diseases.
- Conditions
- HDV, HDV Infection, Hepatitis
- Trial name
- NCT07442760
- Where
- Italy
- Volunteers
- 55 people
- Sponsor
- FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
Chronic Hepatitis D
Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of RBD1016 in Participants With Chronic Hepatitis D
The goal of this clinical trial is to learn if drug RBD1016 works to treat chronic hepatitis D virus infection in adults. It will also learn about the safety of drug RBD1016.
- Trial name
- NCT06649266
- Testing
- RBD1016
- Where
- 2 sites in Sweden
- Volunteers
- 14 people
- Sponsor
- Ribocure Pharmaceuticals AB
Hepatitis Delta Virus
Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a
Two LNF-containing regimens will be evaluated in the D-LIVR Phase 3 study: (1) LNF/RTV/PEG IFN-alfa-2a and (2) LNF/RTV. Each of these arms will have efficacy endpoints that measure clinical benefit with regard to viral…
- Trial name
- D-LIVR (NCT03719313)
- Testing
- Lonafarnib, Ritonavir, PEG IFN-alfa-2a
- Where
- 116 sites in United States, Belgium and 20 more
- Volunteers
- 407 people
- Sponsor
- Eiger BioPharmaceuticals
Delta Hepatitis
Determination of New Detection and Quantification Thresholds for Serological and Molecular Tests for Hepatitis Delta Virus (HDV) Using Capillary Blood on Blotting Paper (DBS)
The Delta hepatitis virus (HDV) is a satellite virus that requires the presence of hepatitis B virus (HBV) for infection. Approximately 5% of HBV-infected individuals, or about 12 million people globally, are also carriers of…
- Trial name
- SACADE (NCT06649396)
- Testing
- Dried Blood Spot, Analysis on plasma
- Where
- France
- Volunteers
- 120 people
- Sponsor
- Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba
Chronic Hepatitis D Infection
Study of Hepalatide in Chronic Hepatitis D(CHD) Patients
A phase 2a clinical Study of Hepalatide for Injection in Subjects with Chronic Hepatitis D
- Trial name
- NCT05827146
- Testing
- Hepalatide
- Where
- 3 sites in China, Mongolia
- Volunteers
- 23 people
- Sponsor
- Shanghai HEP Pharmaceutical Co., Ltd.